VolitionRX Limited (VNRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VNRX POWR Grades
- Sentiment is the dimension where VNRX ranks best; there it ranks ahead of 60.9% of US stocks.
- VNRX's strongest trending metric is Stability; it's been moving down over the last 29.7142857142857 weeks.
- VNRX's current lowest rank is in the Quality metric (where it is better than 9.72% of US stocks).
VNRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for VNRX is 0 -- better than just 7.78% of US stocks.
- VNRX's price/sales ratio is 4,804.8; that's higher than the P/S ratio of 99.68% of US stocks.
- Revenue growth over the past 12 months for Volitionrx Ltd comes in at 117.8%, a number that bests 94.93% of the US stocks we're tracking.
- Stocks that are quantitatively similar to VNRX, based on their financial statements, market capitalization, and price volatility, are RPTX, VHC, TRCH, TGTX, and CRSP.
- VNRX's SEC filings can be seen here. And to visit Volitionrx Ltd's official web site, go to www.volition.com.
VNRX Stock Price Chart Interactive Chart >
VNRX Price/Volume Stats
|Current price||$3.69||52-week high||$6.67|
|Prev. close||$3.49||52-week low||$2.78|
|Day high||$3.97||Avg. volume||385,947|
|50-day MA||$3.46||Dividend yield||N/A|
|200-day MA||$3.65||Market Cap||195.18M|
VolitionRX Limited (VNRX) Company Bio
VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is based in Singapore.
VNRX Latest News Stream
|Loading, please wait...|
VNRX Latest Social Stream
View Full VNRX Social Stream
Latest VNRX News From Around the Web
Below are the latest news stories about Volitionrx Ltd that investors may wish to consider to help them evaluate VNRX as an investment opportunity.
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / VolitionRX Ltd. (NYSE:VNRX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:00 AM Eastern Time.
Our conferences are open to both institutional and retail investors, allowing all investors to obtain meaningful access to management teams" stated Hunter Diamond, CFA the CEO of Diamond Equity Research.Investors can register at https://www.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a business update.
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment, effective May 1, 2021, of Dr. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. Kim Nguyen and Mr. Richard Brudnick to the Company's Board of Directors effective March 25, 2021. Ms. Nguyen was also appointed as Chair of the Company's Compensation Committee and as a member of the Nominations and Governance Committee, and Mr. Brudnick was appointed as a member of the Company's Audit Committee and Compensation Committee.
VNRX Price Returns